Table 4.
Antibacterial activity of CAM-PCL-P NPs (zone of inhibition against the ten clinical isolates of MRSA)
| S No | Bacterial strain | Free CAM | CAM-PCL-P NPs | Increase in fold area |
|---|---|---|---|---|
| 1 | MRSA1 | 0.9 | 1.6 | 2.16 |
| 2 | MRSA2 | 2.75 | 4.7 | 1.92 |
| 3 | MRSA3 | 2.55 | 3.8 | 1.22 |
| 4 | MRSA4 | 3.9 | 5.4 | 0.91 |
| 5 | MRSA5 | 3.65 | 4 | 0.20 |
| 6 | MRSA6 | 3.5 | 4.7 | 0.80 |
| 7 | MRSA7 | 3.05 | 3.85 | 0.59 |
| 8 | MRSA8 | 3.1 | 4 | 0.66 |
| 9 | MRSA9 | 2.65 | 3.6 | 0.85 |
| 10 | MRSA10 | 2.75 | 3.65 | 0.76 |
Abbreviations: CAM, chloramphenicol; CAM-PCL-P NPs, chloramphenicol loaded with poly(ε-caprolactone)-pluronic composite nanoparticles; MRSA, methicillin-resistant Staphylococcus aureus; S No, serial number.